Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
Abstract
Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognostic utility of biomarkers associated with ICI-associated myocarditis. Our objective was to examine the associations between clinical biomarkers of cardiomyocyte damage and mortality in patients with cancer treated with ICIs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2021
- Source ID
- 10.1136/jitc-2021-002553
Entities
People
- Alexander Hattoum
- Ankita Kapoor
- Anne B Curtis
- Arjun Khunger
- Benjamin Switzer
- Brian J Page
- David M. Jacobs
- Edward J Spangenthal
- Filip Stefanovic
- Fumito Ito
- Grace K Dy
- Igor Puzanov
- Jerome J Schentag
- Marc S. Ernstoff
- Mark D Hicar
- Maya R Chilbert
- Nikhil Agrawal
- Pankit Vachhani
- Poornima Subramanian
- Steven G Feuerstein
- Umesh C Sharma
- Yan V Yatsynovich
Organizations
- Lung Cancer Research Foundation
- Melanoma Research Alliance
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Heart, Lung, and Blood Institute
- Roswell Park Alliance Foundation, Roswell Park Cancer Institute
- United States Department of Defense
- University at Buffalo